Computational Drug Repurposing Approach to Identify Novel Inhibitors of ILK Protein for Treatment of Esophageal Squamous Cell Carcinoma

Table 4

ILK affinity in selected compounds and ILK-IN-3 (control) measured by SPR experiments.

Receptor	Ligand	KD (M)	R max (RU)
ILK protein	ILK-IN-3 (control)	2.64E − 06	4.724
	Nilotinib	6.41E − 06	12.52
	Teniposide	1.79E − 06	2.386